3T Therapy in the Treatment of MDA5-positive Dermatomyositis

PHASE4Enrolling by invitationINTERVENTIONAL

Enrollment

133

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2026

Conditions

Dermatomyositis

Interventions

DRUG

Tofacitinib 5 MG

Tofacitinib 5mg BID+thalidomide 50mg BID+tacrolimus 0.1mg/kg QD per oral

Trial Locations (1)

Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou

All Listed Sponsors

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER